A novel pegylated bispecific antibody-drug conjugate (P-BsADC) targeting Her2+cancers with improved efficacy and therapeutic window

被引：0
|
作者：
Wen, Yu
Yin, Shuqiang
Lyu, Weidong
Lei, Yang
Zhuo, Qiudong
Wu, Zibin
Sun, Bin
Tan, Shuangyu
Jiang, Lidong
Zhang, Teng
Gao, Bo
Xu, Rui
Li, Yong
Zheng, Liling
Liu, Shumin
Wu, David
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-4000
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4000
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Preclinical efficacy studies using HuMax-Axl-ADC, a novel antibody-drug conjugate targeting Axl-expressing solid cancers.
    Breij, Esther C. W.
    Verploegen, Sandra
    Lingnau, Andreas
    van den Brink, Edward N.
    Janmaat, Maarten
    Houtkamp, Mischa
    Bleeker, Wim
    Satijn, David
    Parren, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [42] Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer
    Lei, Huizi
    Ling, Yun
    Yuan, Pei
    Yan, Xieqiao
    Wang, Lin
    Shi, Yanxia
    Yao, Xin
    Luo, Hong
    Shi, Benkang
    Liu, Jiyan
    He, Zhisong
    Yu, Guohua
    Han, Weiqing
    Hu, Changlu
    Chi, Zhihong
    Cui, Chuanliang
    Si, Lu
    Fang, Jianmin
    Guo, Jun
    Sheng, Xinan
    Zhou, Aiping
    Ying, Jianming
    JOURNAL OF THE NATIONAL CANCER CENTER, 2023, 3 (02): : 121 - 128
  • [43] In vitro characterization of a novel TROP2-targeting antibody-drug conjugate OBI992
    Kuo, Tzer-Min
    Chang, Ting-Yu
    Huang, Jye-Yu
    Tang, Wei-Chien
    Lin, Chun-Jung
    Wu, Yi-Chen
    Lu, Chi-Huan
    Weng, Hao-Cheng
    Chen, Yu-Jung
    Tsao, Yu-Hsuan
    Wei, Cheng-Yen
    Shen, Lifen
    Li, Wan-Fen
    Lai, Ming-Tain
    CANCER RESEARCH, 2024, 84 (06)
  • [44] EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors
    Capone, Emily
    Lattanzio, Rossano
    Gasparri, Fabio
    Orsini, Paolo
    Rossi, Cosmo
    Iacobelli, Valentina
    De Laurenzi, Vincenzo
    Natali, Pier Giorgio
    Valsasina, Barbara
    Iacobelli, Stefano
    Sala, Gianluca
    PHARMACEUTICS, 2021, 13 (04)
  • [45] SYD985, a novel HER2-targeting antibody-drug conjugate in preclinical models for USC, both in vitro and in vivo.
    Black, Jonathan
    Lopez, Salvatore
    Cocco, Emiliano
    Bellone, Stefania
    Bonazzoli, Elena
    Schwab, Carlton
    English, Diana Peta-gay
    Goedings, Peter J.
    Beusker, Patrick
    van der Lee, Miranda
    Timmers, Marco
    Dokter, Wim
    Schwartz, Peter E.
    Santin, Alessandro
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [46] HER2-/HER3-Targeting Antibody-Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors
    Yonesaka, Kimio
    CANCERS, 2021, 13 (05) : 1 - 13
  • [47] Spatiotemporal Quantification of HER2-targeting Antibody-Drug Conjugate Bystander Activity and Enhancement of Solid Tumor Penetration
    Wei, Qing
    Yang, Teng
    Zhu, Jiayu
    Zhang, Ziwen
    Yang, Le
    Zhang, Yuchao
    Hu, Can
    Chen, Jiahui
    Wang, Jinchao
    Tian, Xuefei
    Shimura, Takaya
    Fang, Jianmin
    Ying, Jieer
    Fan, Mengyang
    Guo, Peng
    Cheng, Xiangdong
    CLINICAL CANCER RESEARCH, 2024, 30 (05) : 984 - 997
  • [48] Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers
    Jhaveri, K.
    Han, H.
    Dotan, E.
    Oh, D-Y.
    Ferrario, C.
    Tolcher, A.
    Lee, K-W.
    Liao, C-Y.
    Kang, Y-K.
    Kim, Y. H.
    Hamilton, E.
    Spira, A.
    Patel, N.
    Karapetis, C.
    Rha, S. Y.
    Boyken, L.
    Woolery, J.
    Bedard, P.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S749 - S750
  • [49] The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan, an anti-HER2 antibody-drug conjugate
    Lee, J.
    Kida, K.
    Liu, H.
    Gi, Y. J.
    Manyam, G.
    Wang, J.
    Multani, A.
    Huo, L.
    Tripathy, D.
    Ueno, N.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S52 - S53
  • [50] Engineering a HER2-specific antibody–drug conjugate to increase lysosomal delivery and therapeutic efficacy
    Jeffrey C. Kang
    Wei Sun
    Priyanka Khare
    Mostafa Karimi
    Xiaoli Wang
    Yang Shen
    Raimund J. Ober
    E. Sally Ward
    Nature Biotechnology, 2019, 37 : 523 - 526
12345